TALAPRO-2: A phase 3 randomized study of enzalutamide (ENZA) plus talazoparib (TALA) versus placebo in patients with new metastatic castration-resistant prostate cancer (mCRPC).

Neeraj Agarwal,Arun Azad,Neal D. Shore,Joan Carles,André P. Fay,Curtis Dunshee,Lawrence Karsh,Maria Luisa Paccagnella,Nicola Di Santo,Mohamed Elmeliegy,Xun Lin,A. Niyazov,Akos Czibere,Karim Fizazi

TALAPRO-2: A phase 3 randomized study of enzalutamide (ENZA) plus talazoparib (TALA) versus placebo in patients with new metastatic castration-resistant prostate cancer (mCRPC).

2021

Neeraj Agarwal
Arun Azad
Neal D. Shore
Joan Carles
André P. Fay
Curtis Dunshee
Lawrence Karsh
Maria Luisa Paccagnella
Nicola Di Santo
Mohamed Elmeliegy
Xun Lin
A. Niyazov
Akos Czibere
Karim Fizazi

TPS5089Background: TALA blocks poly(ADP-ribose) polymerase (PARP) activity and traps PARP on single-strand DNA breaks, preventing DNA damage repair (DDR) and causing death of cells with DDR alterat...

Keywords:

in patient
Cancer research
Polymerase
Medicine
Randomized controlled trial
Enzalutamide
Poly ADP ribose polymerase
Talazoparib
Prostate cancer
Placebo

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations